The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
The September 25 decision adds an oral treatment for patients aged 12 and older with fibrodysplasia ossificans progressiva. A small randomized trial supports an effect on abnormal bone formation, while longer-term functional benefits remain unresolved.
A multi-cohort study connects menopause-related protein patterns with poorer cognitive outcomes in older women. The findings identify research candidates but do not establish a clinical screening test or a preventive treatment.
A small observational study links the osteoporosis peptide drug to increased bone density near the knee after replacement surgery. Whether that translates into fewer fractures or more durable implants remains unresolved.
Newly published research links the metabolic supplement to smaller tumors in female mice and larger tumors in males in one experimental model. The findings underscore uncertainties about translating animal longevity research into human benefits.
Researchers linked Neisseria flavescens to aging-related profiles in people and tested it in worms and mice. The findings nominate a research candidate but do not establish a human longevity intervention.
The approval adds a lutetium Lu 177 dotatate option for adults with certain receptor-positive tumors. It builds on established treatment evidence without demonstrating superior outcomes over Lutathera.
Researchers report changing blood-protein patterns in 197 patients receiving lecanemab. The observational findings suggest possible monitoring tools, but do not establish a validated test of individual treatment benefit.
Researchers mapped gene activity across 284 human brain donors, identifying distinct patterns across development, adulthood and aging. The findings provide a research reference but do not establish a treatment or a test of individual dementia risk.
Newly published research combines experimental retinal-barrier findings with a 24-patient safety study. The results support larger trials but do not establish that the oral drug prevents vision loss.
The approval adds a weekly basal-insulin option backed by randomized trials showing comparable blood-sugar control to daily insulin. Fewer injections do not establish superior long-term health outcomes.
An observational analysis of 2,418 adults connects long-term employment patterns with later cognitive performance. The findings do not establish that postponing retirement prevents dementia.
A newly published study links catestatin to reduced tau pathology and amyloid burden in experimental models. The findings support further peptide research but establish no treatment benefit in people.